Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Because it takes so long for men with even advanced prostate cancer to progress through to death from any cause, there has been extensive effort over the years to define “surrogate” endpoints for prostate cancer-specific and overall survival in prostate cancer clinical trials.
Filed under: Drugs in development | Tagged: enpoint, overall, PSA progression, surrogate, survival | Leave a Comment »
In yet another example of the “maybe or maybe not” world of what helps to trigger increased risk for prostate cancer, we can now place serum calcium levels. Some recent studies (e.g., Skinner and Schwartz) have suggested an association between high levels of serum calcium and a high risk of prostate cancer death. Now an [...]
Filed under: Diagnosis, Risk | Tagged: calcium, risk, serum | Leave a Comment »
Today’s news reports address: Additional new markers associated with prostate cancer risk Relationships between age, total PSA level, and percentage free/total PSA in a cohort of screened patients Are African-Americans at higher risk for positive surgical margins? High-dose brachytherapy after abdominoperineal resection and pelvic external beam radiation
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Leave a Comment »
Your editor was unable to attend the session on prostate cancer prevention and screening at the recent annual meeting of the American Society for Clinical Oncology (ASCO) because he is still working on how to be in two places at once.
Filed under: Diagnosis, Prevention, Risk | Tagged: PCPT, Prevention, REDUCE, screening, SELECT | 3 Comments »
There continue to be a multitude of news reports from the ASCO meeting today — some of which seem to be based more on media releases than on what was actually presented by the investigators who carried out the research (caveat emptor). The news items mentioned below deal with items unrelated to ASCO: The prognostic [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: adjuvant radiation therapy, neuroendocrine prostate cancers, surgery, undetectable PSA | Leave a Comment »
Bristol-Myers Squibb has announced the launch of the READY Phase III trial designed to compare dasatinib (Sprycel) + docetaxel (Taxotere) + prednisone as first-line chemotherapy compared to placebo + docetaxel + prednisone in men with metastatic castration-resistant prostate cancer (CRPC).
Filed under: Drugs in development, Management, Treatment | Leave a Comment »
For the patient who has prostate cancer, and for his family, things are very personal. These patients have important clinical needs that we must try to meet. But when we talk about prostate cancer more generally — to our friends, to our family members, to our state and federal legislators and public health officials, it [...]
Filed under: Diagnosis, Living with Prostate Cancer, Prevention, Risk, Uncategorized | Leave a Comment »
At a meeting of some leading members of the prostate cancer advocacy community yesterday morning, during the ASCO meeting in Orlando, Dr. William Simons of the Prostate Cancer Foundation distributed a diagram suggesting that there may be as many as 15-18 different sub-types of prostate cancer.
Filed under: Drugs in development, Management, Prevention, Risk | Leave a Comment »
There were about 50 prostate cancer-specific posters presented in the general poster session on Sunday, and we will give a quick overview of some of the more interesting ones.
Filed under: Drugs in development, Management, Treatment | Tagged: ASCO, CRPC, neoadjuvant chemotherapy | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site